California Biotech Insights

M&A, Deals, Partnerships: Juri Biosciences (SF) Signs Licensing Deal with EpimAb Biotherapeutics (Shanghai) for KLK2-Directed T-Cell Engager in Prostate Cancer Juri Biosciences, a TCG Labs Soleil portfolio company, has secured exclusive global rights to EpimAb’s T-cell engager targeting KLK2 for metastatic prostate cancer, with the potential for up to $210 million in payments. The partnership […]

M&A, Deals, Partnerships: Altos Labs (SF) Acquires Dorian Therapeutics (SF) to Boost Aging and Longevity Research Altos Labs has acquired Dorian Therapeutics, a startup focused on senoblockers, which aim to reverse aging and regenerate youthfulness in diseases like Alzheimer’s, osteoporosis, and diabetes. The acquisition brings Dorian’s research on cellular rejuvenation under Altos’ umbrella, which was […]

M&A, Deals, Partnerships: BioMarin (SF) Acquires Inozyme for $270M, Adds Phase 3 Enzyme Therapy to Rare Disease Pipeline In its first major M&A under new CBO James Sabry, BioMarin will acquire Inozyme for $270M to gain INZ-701, a Phase 3 enzyme replacement therapy for ENPP1 deficiency, a rare genetic disease with severe cardiovascular risks in […]

Recent Funding: Vivo Capital (SF) Closes $740M Public Fund to Back Clinical-Stage Biotechs The third cycle of the Vivo Opportunity Fund will target small- and mid-cap life sciences companies, aiming to capture value around clinical milestones and regulatory approvals. Previous Vivo-backed companies include Soleno, RayzeBio, Chinook, and Sierra Oncology, with several achieving FDA approvals or […]

Recent Funding: Deerfield Management (NY) Raises $600M Fund to Back Biotech and Healthcare Startups The fund will support early drug development, medical devices, and healthcare services, with a strong focus on collaborations with 30+ academic institutions and company creation via its NYC “Cure” campus. Deerfield’s past investments include BridgeBio Oncology, Frontier Medicines, and Perceive Pharma, […]